Moex

Quick links to important sections

Moex

Method of action: Hypotensive

Treatment option: Hypertension

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Moex

What is Moex? An Overview

Property Description
Active ingredient Moexipril Hydrochloride
Form Oral tablet (Film-coated)
Pharmacological class Angiotensin-Converting Enzyme (ACE) Inhibitor
Common use Circulatory management / Blood pressure stabilization
Origin Synthetic compound

What Type of Medicine is Moex (Moexipril)?

Moex, containing the active ingredient Moexipril Hydrochloride, is a synthetic pharmaceutical agent classified as an Angiotensin-Converting Enzyme (ACE) Inhibitor. This places it among the primary classes of medications used to stabilize blood pressure and manage circulatory conditions.

The compound is structurally defined as a non-sulfhydryl containing precursor and functions as a prodrug. This distinction means the drug administered as an oral tablet is initially inactive; it must undergo a metabolic process called hydrolysis to convert into the pharmacologically potent substance, Moexiprilat. ACE inhibitors, like Moexipril, are widely prescribed agents for managing hypertension. This indicates that the medication is designed to support the stabilization of the body’s blood pressure over time, a typical use scenario.


Understanding Moexipril's Form and Origin

Moexipril is supplied as an oral tablet, often film-coated, making the mouth the required route of administration. As a product of chemical synthesis, Moexipril is classified as a synthetic compound, rather than being derived directly from biological or natural sources.

The formulation is typically intended as a single-ingredient product (monotherapy) when addressing its core indication, though combination forms exist. The high-level composition of the tablet includes the Moexipril Hydrochloride active ingredient alongside solid excipients necessary for the tablet structure and stability.


What is the General Purpose of ACE Inhibitors?

The general purpose of this class of medicine is to reduce the force and pressure exerted on the heart and blood vessels. It achieves this by interfering with the Renin-Angiotensin-Aldosterone System (RAAS), a hormonal cascade that regulates vascular tension.

The key action involves blocking the enzyme responsible for creating Angiotensin II, a compound that causes blood vessels to constrict (tighten). By blocking its formation, the medicine promotes vasodilation, which is the relaxation and widening of blood vessels, thereby lowering systemic vascular resistance and facilitating easier blood flow throughout the circulatory system.

Regulatory References

  1. ACE inhibitors: MedlinePlus

What side effects are possible with Moex?

Moexipril: Possible Side Effects and Safety Information

The safety profile of Moexipril is formally categorized by regulatory authorities to distinguish between common, less common, and serious adverse reactions. As an Angiotensin-Converting Enzyme (ACE) inhibitor, its safety profile includes effects shared by the drug class, as well as specific documented concerns.


Documented Adverse Reactions

Adverse reactions are classified by the frequency of their occurrence in clinical studies and post-marketing surveillance:

  • Common Reactions (1% to 10%): These frequently reported effects include a persistent nonproductive cough, dizziness, headache, and fatigue. Gastrointestinal issues such as diarrhea and nausea are also listed as common.
  • Uncommon to Rare Reactions: These effects occur less frequently and include symptomatic hypotension (low blood pressure), abdominal pain, vomiting, and disturbances such as alteration of taste.

Reactions are officially grouped by the body system affected, including Respiratory, Nervous System, and Gastrointestinal disorders.


Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight reactions that are considered rare but medically significant:

  • Angioedema: This potentially life-threatening reaction involves rapid swelling of the face, lips, tongue, or throat. Angioedema is a primary safety concern for ACE inhibitors and is a contraindication for future use if it occurs.
  • Fetal Toxicity: Use of Moexipril during the second and third trimesters of pregnancy is associated with documented risks of fetal injury and mortality, leading to a contraindication during this period.
  • Hypotension: Profound symptomatic low blood pressure is a serious risk, especially upon initiation of treatment or in patients with existing volume depletion.

Safety constraints also include the contraindication for individuals with a history of angioedema related to prior ACE inhibitor exposure, or those taking specific medications such as Neprilysin Inhibitors. Caution is also required in patients with renal impairment, as the drug can be associated with documented increases in serum creatinine and BUN.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Moexipril overdose focuses on severe physiological instability and the required immediate emergency response. The primary manifestation of an excessive dose is excessive hypotension, which is a profound lowering of blood pressure. Clinical signs associated with this may include dizziness, lightheadedness, and syncope (fainting). A laboratory finding of hyperkalemia is also documented as a potential complication within the drug class.

Urgent medical attention must be sought immediately if an overdose is suspected or if signs of a life-threatening complication appear. The most serious acute risk documented is angioedema (swelling) involving the tongue, glottis, or larynx, which carries the potential for fatal airway obstruction. For this specific event, official emergency protocol involves prompt administration of subcutaneous epinephrine and measures to ensure a patent airway.

Management for Moexipril overdose is symptomatic and supportive, as no specific antidote is known. For severe hypotension, official guidance describes placing the patient in the supine position and, if necessary, administering intravenous saline infusion. Additionally, exposure during the second or third trimesters of pregnancy is explicitly linked to the risk of fetal and neonatal injury and death, including renal failure, requiring specialized clinical procedures.

Therapeutic Uses of Moex

What Moex Treats: Main Uses and Benefits

Moexipril is commonly used for managing Sustained Blood Pressure Stabilization in individuals with Essential Hypertension. The medicine is considered relevant for addressing symptoms related to systemic imbalance, specifically chronically elevated pressure readings. It supports the long-term management of this condition and helps control high blood pressure readings and increased systemic vascular resistance.

Key Therapeutic Focus

Moexipril may assist with addressing the symptoms related to systemic imbalance by contributing to improved comfort through supporting risk management over time. By helping to lower and maintain stable blood pressure, it supports a reduction in the chance of serious events. This provides the therapeutic benefit of mitigating risk for stroke, heart attack (myocardial infarction), and the progression of heart failure. The medication is commonly used across domains where additional symptomatic support is needed to support the long-term functional stability of the heart and kidneys, which are symptoms linked to organ-specific functional stress due to high pressure.

“The goal of management is continuous stabilization, helping patients cope more steadily with symptom fluctuations associated with this chronic condition.”


Quick Fact: Relief for Chronic Vascular Strain Moexipril helps ease the symptoms that create noticeable physiological strain on the cardiovascular system by assisting with the maintenance of lower systemic pressure.

Regulatory References

  1. Sustained Blood Pressure Stabilization

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Moexipril (Moex)

Official regulatory documents define strict limitations on who may use Moexipril, an Angiotensin-Converting Enzyme (ACE) inhibitor.

Contraindicated Populations (Must Not Use) Eligibility-Related Restrictions (Use with Caution)
History of angioedema (swelling) related to any prior ACE inhibitor. Patients with renal impairment (kidney disease) or volume depletion (e.g., severe vomiting/diarrhea) may require a lower starting dose.
Pregnancy during the second and third trimesters (due to risk of fetal injury/death). Hepatic impairment (liver dysfunction) requires caution and careful monitoring due to altered drug metabolism.
Patients with diabetes receiving aliskiren. Older adults may require dose adjustments due to the higher likelihood of age-related renal function decline.
Patients who have taken sacubitril/valsartan within 36 hours. Pediatric use (children and adolescents) is not established as safety and effectiveness have not been proven.

Pregnancy and Lactation Status: Moexipril is contraindicated when pregnancy is detected in the later trimesters. Use during breastfeeding is not recommended due to insufficient data on infant risk.

What should I know about interactions with other medicines?

Moex Interactions with other medicines and products

Official regulatory documents define specific substance classes and timing requirements that must be considered during Moexipril administration. These constraints are primarily related to pharmacokinetic modification and critical pharmacodynamic risks, such as fluid and electrolyte imbalance.

Classification Interacting Agents / Classes Regulatory Constraint
Prohibited Combinations Sacubitril/Valsartan Requires a mandatory 36-hour separation period to avoid co-administration.
Aliskiren Formally contraindicated in patients with diabetes mellitus.
High-Risk Additive Effects Potassium Supplements and Potassium-Sparing Diuretics Documented increased risk of hyperkalemia (elevated serum potassium levels).
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) May lead to the attenuation of the antihypertensive effect and potential deterioration of renal function.
Exposure Modification Food (Meals) Markedly reduces the absorption and overall exposure (AUC and C max) of the active metabolite, Moexiprilat, necessitating a fasting administration rule.

Co-administration with other agents affecting the Renin-Angiotensin System, such as Angiotensin II Receptor Blockers (ARBs), is associated with heightened risks of hypotension and adverse changes in renal function. The regulatory profile also notes that patient populations with renal or hepatic impairment exhibit significantly increased exposure to the active metabolite, a finding that informs specific interaction potential.

Mechanism of Action

Moex is a human monoclonal antibody that specifically targets and binds with high affinity to the Receptor Activator of Nuclear Factor kappaB Ligand (RANKL). This targeted binding prevents RANKL from interacting with its receptor, RANK (Receptor Activator of Nuclear Factor kappaB), which is prominently expressed on the surface of pre-osteoclasts and mature osteoclasts.

Direct inhibition of the RANKL/RANK signaling pathway blocks the necessary cascade for the differentiation, activation, and survival of osteoclasts (the primary cells responsible for bone resorption). Consequently, Moex reduces both the total number and function of active osteoclasts.

This molecular interaction results in the inhibition of bone resorption. By affecting the cellular balance between bone formation (osteoblasts) and bone resorption, the drug alters bone tissue remodeling and affects mineral density at a systemic physiological level.

Dosage and Administration Information

How to Use Moexipril (Moex)

Moexipril is administered by the oral route using a tablet formulation. The medicine is generally taken as part of a long-term management plan for the condition it addresses.


Administration Guidelines

Administration of Moexipril follows specific patterns regarding dose ranges and timing relative to meals. A key constraint is that the tablet is taken on an empty stomach, specifically one hour prior to a meal, because food reduces the absorption and availability of the active substance.

Dosing and Frequency Patterns

The standard adult dosing schedule typically involves administration once daily. However, if the blood pressure lowering effect diminishes before the end of the 24-hour interval, the total daily dose may be adjusted to be taken in two equally divided doses.

  • Initial Dose: For patients not receiving diuretics, the starting amount is typically 7.5 mg once daily. A reduced initial amount of 3.75 mg once daily is used for patients who are volume-depleted or receiving diuretics.
  • Maintenance Range: The typical daily maintenance dose is between 7.5 mg and 30 mg, with a maximum recommended daily dose of 60 mg for essential hypertension.

Adjustments and Procedural Rules

Dosage is adjusted based on the patient's response, often involving titration over the first four weeks of therapy. Dose adjustments are utilized for patients with renal impairment. For individuals with a creatinine clearance less than or equal to 40 mL/min, the starting dose is 3.75 mg once daily, and the maximum daily dose does not exceed 15 mg.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Moex

Evidence for Use in Essential Hypertension

Moexipril (Moex) was studied in research contexts involving fluctuating or unstable symptoms in individuals with high blood pressure, a condition marked by functional limitations. The primary research available consists of Randomized Controlled Trials (RCTs). These short- to intermediate-term studies are conducted to see how the compound was evaluated when compared against a placebo or other medicines.

Research primarily examined the compound in adults with mild to moderately severe hypertension. The core measurement used in these trials was the change in Systolic and Diastolic Blood Pressure (BP), which research describes how blood pressure readings evolved in the observed populations over the study period. Findings reported measurements related to the change in BP and data show patterns related to how sustained blood pressure levels were over a 24-hour cycle. However, comparative evidence is lacking for the compound against all alternative types of blood pressure medications in large, long-term trials.

Research Focus on Risk Mitigation

Beyond the primary use of examining blood pressure, research examined the role of Moexipril in contexts associated with the incidence of future, more serious cardiovascular events, such as stroke or heart attack. Researchers explore the sustained effect of pressure levels over time as a surrogate marker for risk. Studies explored the maintenance of blood pressure readings over longer periods, sometimes extending up to two years.

Crucially, there is limited information for long-term outcomes from dedicated Moexipril trials focused specifically on the incidence of events. While research explores a class effect for ACE inhibitors related to the incidence of these risks, the current data for Moexipril itself relies heavily on surrogate outcomes (like sustained BP measurements) to provide insight into long-term effects. Therefore, long-term effects are not fully established by Moexipril-specific trials.

Evidence in Special Populations

Research examined the compound's use in different populations. Trials included older adults and patients with varying levels of mild to moderate kidney or liver function impairment for pharmacokinetic studies. However, the safety and effectiveness of Moexipril are not established for use in the pediatric population (children and adolescents). Subgroup findings are uncertain regarding the rate of trough BP measurements in black patients compared to others, indicating an area where data for certain groups remain insufficient.

Key Studies & References

  1. Moexipril (Oral Route) - Drug Information
  2. World Health Organization Model List of Essential Medicines (Entry for ACE Inhibitors)

Frequently Asked Questions (FAQ)

Common questions about Moex (FAQ)


Q: If I miss taking Moex, should I take it later?

A: If a dose is remembered, official patient information suggests taking it as soon as it is recalled. If it is almost time for the next scheduled dose, the missed dose should be skipped entirely. Extra medicine is not advised to compensate for a missed dose.


Q: What is the time frame for people to start noticing the effects of Moex?

A: The onset of action for blood pressure reduction is measurable soon after administration. Research has measured the maximum blood pressure-lowering effect occurring approximately 6 hours after the drug is administered.


Q: Does Moex interact with common pain relievers?

A: Regulatory documents note a documented interaction with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Official documents note that co-administration with an NSAID is associated with reduced blood pressure-lowering effects and potential changes in renal function.


Q: Are there any foods or drinks that interact with Moex?

A: Official patient information specifies the drug is to be taken on an empty stomach, one hour before a meal, as food intake is associated with reduced absorption. Additionally, caution is noted regarding the use of salt substitutes containing potassium, which may increase the risk of high potassium levels in the blood.


Q: Is it safe to drink alcohol while taking Moex?

A: Official warnings note that drinking alcohol while taking Moexipril may increase the risk of low blood pressure symptoms, such as feeling dizzy or lightheaded, due to a potential additive effect.


Q: Can Moex be taken with supplements or vitamins?

A: Regulatory documents explicitly caution against taking potassium supplements or salt substitutes containing potassium. These products are advised to be used only in consultation with a healthcare professional, due to the documented risk of developing elevated potassium levels.


Q: How long does Moex stay in your system?

A: The clearance of the active substance from the body is linked to its elimination half-life. Regulatory documents report that this half-life is highly variable among patients, ranging from approximately 0.8 hours to 53 hours in studies.


Q: Does Moex cause dizziness or affect driving?

A: Dizziness is officially listed as a commonly reported side effect. Official warnings advise against driving or operating machinery until individuals know how the drug affects them, as it may impair coordination and judgment.


Q: Do the side effects of Moex usually go away after a while?

A: While there is no blanket statement for all common effects, clinical documentation has noted that some temporary laboratory changes associated with the drug, such as minor elevations of liver enzymes, are described as transient (short-lasting).


Q: Can I stop taking Moex if I feel better?

A: Moexipril is used for long-term conditions like high blood pressure, which often presents no noticeable symptoms. Official patient counseling emphasizes that the medication should be continued according to the prescribed plan, even when a patient feels well, to ensure effective long-term management.


Q: Is Moex ever prescribed for children?

A: Safety and effectiveness in the pediatric population (children and adolescents) are not established in official documents.


Q: Can elderly patients take Moex?

A: Yes, older adults are included in clinical trials and may use Moexipril. However, official guidance indicates that dose adjustments may be required due to the higher likelihood of age-related changes, especially in kidney function.


Q: What does the research say about the long-term use of Moex?

A: Official documents indicate there is limited information from dedicated Moexipril trials focused on long-term clinical outcomes, such as the actual incidence of cardiovascular events. Research often relies on sustained blood pressure reduction as a surrogate measure for potential long-term benefits.


Q: Is there a generic version of Moex available?

A: Yes, Moexipril is the active ingredient, and generic versions of the Moexipril Hydrochloride tablet are available through regulatory approval processes.


Q: What is the difference between Moex and a placebo in clinical trials?

A: In clinical trials, the primary measurable difference between Moexipril and an inactive placebo was the recorded therapeutic change in Systolic and Diastolic Blood Pressure (BP) measurements.


Q: Is Moex used for chronic or acute conditions?

A: Moexipril is indicated for the treatment of essential hypertension, a condition that requires ongoing care. For this reason, it is generally intended as part of a long-term, chronic management plan.


Q: What happens if I accidentally take two doses of Moex?

A: If too much is taken, the main concern is a risk of severe low blood pressure (hypotension). In the event of an accidental overdose, seeking emergency medical attention or calling a poison control line immediately is noted as the official procedure.


Q: Why is the dosage of Moex different for different people?

A: Official guidance states that the dosage must be adjusted based on the patient's individual blood pressure response. Adjustments are also mandatory for specific patient conditions, such as the presence of kidney impairment (renal function), volume depletion, or taking certain diuretics.


Q: Can Moex be crushed or split?

A: The approved tablet formulation is generally described in regulatory documents as scored, meaning it has a groove or line across it. This physical characteristic is often intended to allow the tablet to be broken.


Q: Are there any common misuses of Moex that people online talk about?

A: Official patient warnings caution against non-compliance, such as using the medication in larger or smaller amounts or for longer than recommended by the prescriber. It is intended for continuous use as directed.


Q: What conditions should a doctor know about before prescribing Moex?

A: Official documents require the disclosure of specific conditions, including a history of angioedema (swelling) related to any ACE inhibitor, and the presence of pre-existing kidney or liver impairment.


Q: Is it normal to feel a mild headache when first starting Moex?

A: Headache is listed in official documents as a common adverse reaction associated with Moexipril. The initial dose is sometimes directed to be taken at bedtime because of the potential for dizziness, which is consistent with the expectation of common initial effects.


Q: Do I need to change my diet while on Moex?

A: Official warnings dictate that the medication must be taken on an empty stomach. Caution is also advised regarding the use of salt substitutes containing potassium, and patients beginning a low-salt diet should consult their healthcare professional.


Q: How quickly can the effects of Moex wear off after stopping treatment?

A: The time it takes for the effects to wear off is related to the elimination half-life of the active substance. Since the half-life is highly variable, ranging widely from approximately 0.8 hours to 53 hours in studies, the clearance time is not uniform for all patients.

How should Moex be stored and disposed of?

Official Storage and Disposal Instructions

Moexipril Hydrochloride (Moex) tablets must be stored according to regulatory specifications to maintain their stability.

Requirement Official Rule
Temperature Store at Controlled Room Temperature (20 C to 25 C).
Protection Keep protected from excess moisture and direct light.
Container Keep the medication in the original, tightly closed container.
Prohibited Do not store in the bathroom or allow the medicine to freeze.
Child Safety Mandatory to keep out of the sight and reach of children.

For disposal, Moex must not be flushed down the sink or toilet, as it is not on the wastewater disposal list. The recommended method for discarding unused or expired tablets is to utilize an official drug take-back program or place them in household trash after mixing with an undesirable substance in a sealed container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Moex found in:

A-Z Index: